Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: A phase 1 study

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 704-715

  Palanca Wessels, Maria Corinna A ^a   Czuczman, Myron ^b   Salles, Gilles ^c   Assouline, Sarit ^d   Sehn, Laurie H ^e   Flinn, Ian ^f   Patel, Manish R ^g   Sangha, Randeep ^h   Hagenbeek, Anton ⁱ   Advani, Ranjana ^j   Tilly, Herve ^k   Casasnovas, Olivier ^l   Press, Oliver W ^a   Yalamanchili, Sreeni ^m   Kahn, Robert ^m   Dere, Randall C ^m   Lu, Dan ^m   Jones, Surai ^m   Jones, Cheryl ^m   Chu, Yu Waye ^m   Morschhauser, Franck ⁿ   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITÉ LYON 1   (France)

^d MCGILL UNIVERSITY   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j STANFORD CANCER INSTITUTE   (United States)

^k UNIVERSITÉ DE ROUEN   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m GENENTECH INC   (United States)

ⁿ Univ Lille   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

POLATUZUMAB VEDOTIN; RITUXIMAB; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD79 ANTIGEN; CD79B PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; LARGE CELL LYMPHOMA; LUNG DISEASE; LUNG INFECTION; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; OPEN STUDY; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD79; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84930274224     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70128-2     Document Type: Article

References (23)

1. Chu YW, Polson A Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. Future Oncol 2013, 9:355-368.
2. Cabezudo E, Carrara P, Morilla R, et al. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 1999, 84:413-418.
3. D'Arena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B- cell chronic lymphoproliferative disorders. Am J Hematol 2000, 64:275-281.
4. Olejniczak SH, Stewart CC, Donohue K, et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 2006, 35:93-114.
5. Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti CD79b antibody drug conjugate, anti CD79b vc MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009, 114:2721-2729.
6. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009, 69:2358-2364.
7. Bai RL, Pettit GR, Hamel E Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990, 265:17141-17149.
8. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
9. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10 vcMMAE, an anti CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102:458-465.
10. Friedberg JW Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011, 1:498-505.
11. Gopal AK, Kahl BS, de Vos S, et al. PI3K-delta inhibition by idelalisib in patients relapsed indolent lymphoma. N Engl J Med 2014, 370:1008-1018.
12. Van Oers MHJ, Glabbeke MV, Giuregea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J Clin Oncol 2010, 28:2853-2858.
13. NCI common terminology criteria for adverse events (CTCAE) v4.0 2014, National Cancer Institute, National Cancer Institute, Bethesda, MD.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
15. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia; a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
16. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
17. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
18. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
19. Pfeifer M, McCord R, Koeppen H, et al. Anti-CD22 and anti-CD79b antibody-drug-conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 2015, published online Feb 24. 10.1038/leu.2015.48.
20. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015, 125:1394-1402.
21. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010, 28:2085-2093.
22. Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014, 20:213-220.
23. Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer 2009, 115:3475-3482.